COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
Jaguar Health, Inc. (NASDAQ:JAGX) has announced the publication of a study evaluating the effects of crofelemer in providing symptomatic relief of diarrhea associated with the irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor neratinib (Nerlynx®) in female dogs. The study, conducted by Napo Pharmaceuticals in collaboration with Puma Biotechnology, highlights the growing need for treatment of cancer therapy-related diarrhea (CTD), a common and debilitating side effect of patients undergoing cancer therapy. The findings of this study, along with two other important studies, provide scientific rationale for the use of crofelemer in humans for the prevention and treatment of CTD, addressing the unmet medical need in the age of targeted cancer therapies. -
COMMUNIQUÉ DE PRESSE
Revolutionizing NDT Inspection: Voliro's Innovative Technology Eliminates Downtime
Voliro introduces the high-temperature Ultrasonic Testing (UT) payload for the Voliro T drone, revolutionizing the Non-Destructive Testing (NDT) sector by enabling inspections on hot surfaces without costly downtime. This groundbreaking technology offers a safer, more efficient, and cost-effective approach to inspections in challenging industrial environments. -
COMMUNIQUÉ DE PRESSE
FAVO Capital, Inc. Opens A Second Call Centre Location in Dominican Republic and Continues to Implement its Growth Strategy
FAVO Capital Inc., a respected alternate finance company, is expanding its reach with the opening of a new call centre location in the Dominican Republic. This strategic move showcases its commitment to providing exceptional financial solutions and services, offering innovative products, and investing in technology and talent to meet the needs of its clientele. The company is also dedicated to community engagement, aiming to make a positive impact beyond financial services. With this expansion, FAVO Capital reinforces its position as a leader in the industry and invites clients, partners, and the media to stay updated on their journey towards innovation and excellence. -
COMMUNIQUÉ DE PRESSE
CMI Investor Alert: Kaplan Fox Investigates Potential Securities Fraud At Cummins, Inc.
Kaplan Fox & Kilsheimer LLP is conducting an investigation into potential securities fraud at Cummins Inc. following the announcement of a $1.675 billion penalty to settle claims of violating the Clean Air Act. If you are an investor of Cummins Inc. and would like to discuss the investigation, contact Kaplan Fox for more information. With over 50 years of experience in securities litigation, Kaplan Fox is a leading national law firm with a track record of successfully shaping the law through winning important decisions on behalf of clients. -
COMMUNIQUÉ DE PRESSE
Louisiana, USA: Cloud-based deployment of Kapsch’s Commercial Back Office System and End-to-End tolling solution enters full operation
Kapsch TrafficCom successfully deploys a cloud-based Commercial Back Office System and End-to-End tolling solution in Louisiana, USA. The LA1 tolling facility, serving as a crucial transportation artery for the state and country, has been revamped with state-of-the-art toll collection and enhanced customer service capabilities. -
COMMUNIQUÉ DE PRESSE
BioAdaptives' Subsidiary, Livestock Impact, Inc., Celebrates Banner 2023 Equine Championship Titles Attributed to Its Advanced Proprietary Supplement Products
BioAdaptives Inc. celebrates the achievement of multiple Equine Championship Titles attributed to its subsidiary Livestock Impact, Inc.'s advanced proprietary supplements. The highlight was the spectacular performance of Cheyanne Colclasure with her 23-year-old horse, Docs Dual Quixote, who secured the 35,000 Non Pro National Championship Title at the 2023 United States Cutting Horse Association (USCHA) National Championship competition. Livestock Impact's All-In-One supplement formulas have shown rejuvenating effects such as improved energy, agility, and response time in animals. BioAdaptives, Inc. manufactures and distributes natural plant- and algal-based products that improve health and wellness for humans and animals, with an emphasis on pain relief, antiviral activity, immune system defense, resistance to stress, endurance, recovery, and anti-aging properties. The company's products for horses and dogs provide general health, competitive performance enhancement, rejuvenation effects, and pain relief, as well as improvements in appearance. -
COMMUNIQUÉ DE PRESSE
Balto Releases QA Copilot, Superhuman Levels of Accuracy and Consistency
Balto unveils the latest leap forward in QA automation for contact centers with Balto QA Copilot. This new generative AI tool allows users to auto-score calls based on natural language criteria, revolutionizing traditional QA methods. Balto QA Copilot redefines the future of quality assurance in contact centers, enabling teams to focus on meaningful interactions rather than tedious scoring. Learn more about Balto QA Copilot in an educational webinar on January 25th. -
COMMUNIQUÉ DE PRESSE
01 Communique Provides Update on Business Developments and Fourth Quarter Fiscal 2023 Results
01 Communique Laboratory Inc. reported its fourth quarter fiscal 2023 results, highlighting the development and implementation of IronCAP™, a quantum-safe encryption service, to address the rising threat from quantum computers. The Company's operational and financial highlights demonstrate its commitment to post-quantum cybersecurity and reduction of operating expenses, positioning itself for ongoing recurring royalty revenue. The press release includes information on the financial performance and details about a live teleconference, allowing stakeholders to gain insights into the Company's results and future prospects for IronCAP™ and IronCAP X™. -
COMMUNIQUÉ DE PRESSE
Catheter Precision, Inc. (VTAK) Secures New Distributor for VIVO in Turkey
Catheter Precision, Inc. (NYSE American: VTAK) has signed a new distributor for Turkey for its non-invasive 3D localization system, VIVO, expanding its footprint in Eastern Europe. The company's focus on expanding sales territory and utilizing local personnel familiar with regulations helps streamline the approval process. VIVO, a non-invasive 3D imaging system, enables physicians to identify the origin of ventricular arrhythmias pre-procedure, reducing procedure time. For more information on the company and its products, visit www.catheterprecision.com.
